May 11, 2026

British Ambassador Pays an Official Working Visit to Alkaloid

The discussions during the working meeting centred on Alkaloid’s long-term strategic priorities, including its strong export orientation, capital investments, education initiatives, implementation of ESG standards, socially responsible projects, and sustainable growth through international market expansion and differentiation.


A delegation from the British Embassy in Skopje, headed by H.E. Ambassador Matthew Lawson, paid an official working visit to Alkaloid AD Skopje, where they were welcomed by the company’s CEO and MB President, Mr Zhivko Mukaetov. During the visit, the delegation was introduced to the company’s development trajectory, international market presence, and diverse product portfolio. The program also included a tour of the Museum of Alkaloid, the production facilities within the Pharmaceuticals Profit Centre, and the Research and Development Institute.


Alkaloid AD Skopje has maintained a presence in the United Kingdom market since 2007, when the UK Medicines and Healthcare products Regulatory Agency (MHRA), selected by the company as its reference regulatory authority, granted the Pharmaceuticals segment certification confirming compliance with EU Good Manufacturing Practice (EU-GMP) standards, following an inspection of the production facilities. Soon afterwards, the company obtained its first marketing authorisation for the medicinal product Lisinopril. Today, Alkaloid holds more than 1,000 marketing authorisations for its pharmaceutical products across European Union markets.



Following the United Kingdom’s departure from the European Union, Alkaloid established its subsidiary, Alkaloid UK Limited, in 2021, creating new opportunities for further business expansion and market positioning. The British market is regarded as one of the most demanding and competitive pharmaceutical markets, with exceptionally rigorous entry requirements due to the industry’s strict regulatory framework. Current projections estimate that sales of Alkaloid’s pharmaceutical products in the United Kingdom will reach approximately EUR 4 million by the end of 2026.

Since 2023, Alkaloid AD Skopje has also been a member of the British Business Association, which collaborates closely with the British Embassy in Skopje to support the development of a competitive, transparent, and modern business environment. The Association has established itself as a recognised platform for promoting innovation, responsible business practices, and emerging economic trends.